source
- Lilly shares safety data on next-gen obesity drug retatrutide; Revolution Medicines reports strong pancreatic cancer resultsLilly provided new data that detail the safety and tolerability profile of its next-generation obesity therapy, retatrutide. The information adds to the growing body of evidence supporting the drug…
- AstraZeneca’s oral GLP-1 candidate elecoglipron cuts weight 11% in Phase 2 obesity trialA Phase 2 study (VISTA) of AstraZeneca’s oral GLP‑1 molecule elecoglipron in people with obesity showed an average weight loss of 11.2 % after 36 weeks, according to data presented at the American…